MedPath

A Retrospective Chart Review to Evaluate Diagnosis and Treatment of Chronic Migraine and Headache

Completed
Conditions
Headache
Migraine Disorders
Registration Number
NCT01946126
Lead Sponsor
Allergan
Brief Summary

This study is a retrospective chart review in patients diagnosed with headache or migraine to evaluate treatment patterns and diagnosis.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
459
Inclusion Criteria
  • Diagnosis of chronic migraine or other diagnosis of migraine or headache for a minimum of 15 months
  • Eight (8) headache days per month for at least 1 of the preceding 15 months
Exclusion Criteria
  • Not currently diagnosed with chronic migraine, headache or migraine
  • History of receiving botulinum toxin injections for the treatment of chronic migraine.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Presence or Absence of Prophylactic Medication for Headache/Migraine15 Months

The presence or absence of prophylactic medications used by the subject for headache/migraine is evaluated through the study period.

Secondary Outcome Measures
NameTimeMethod
Number of Visits for Headache Diagnosis15 Months

The number of visits for headache diagnosis is evaluated through the study period.

Number of Unique Prophylactic Medications for Headache/Migraine Reported15 Months

The numbers of unique prophylactic medications used by the subjects for headache/migraine are evaluated through the study period.

Number of Days With a Headache Recorded at the Visit With the Highest Number of Headaches15 Months

The number of headache days is reported at the visit with the highest number of headaches.

Highest Number of Headache Days Per Month at a Qualifying Visit15 Months

The highest number of headache days per month are reported at a qualifying visit per the medical record.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.